Background. Colchicine has been used in conditions such as periodic febrile illness, acute pericarditis, and gouty arthritis, all having a common hyperinflammatory response as seen in moderate to severe forms of coronavirus disease 2019 (COVID-19). This project was carried out during the rapid surge of cases in New York City, and the goal was to assess the efficacy of colchicine in treating patients with COVID-19. Methods. Patients admitted to two distinct pulmonary oriented floors of the BronxCare Hospital Center were compared. Patients on one floor were given colchicine in addition to standard of care, while control patients from another floor received only standard of care. Patients who had at least two separate timepoint measurements for at least two out of four serum inflammatory markers (C-reactive protein (CRP), D-dimer, ferritin, or lactate dehydrogenase (LDH)) were selected for the final comprehensive analysis. Results. An initial analysis performed on all patients, irrespective of the availability of two timepoint inflammatory markers, revealed a lower mortality (49.1% versus 72.9%, ), a lower percentage of intubations (52.8% versus 73.6%, ), and a higher discharge rate (50.9% versus 27.1%, ), in the patients who received colchicine. Patients in the final comprehensive analysis groups (34 in the colchicine group and 78 in the control group) had a similar prevalence of comorbid medical conditions, except for renal failure, which was higher in the control group (65.3% versus 35.2%, ). HTN (71.8% versus 52.9%, ) and DM (51.3% versus 32.4%, ) were also more prevalent in the control group, although the difference was not statistically significant. Patients who received colchicine had a lower mortality than the control group (47.1% versus 80.8%, ), lower rate of intubations (47.1% versus 87.2%, ), and a higher discharge rate (52.9% versus 19.2%, ). Patients in the colchicine group also showed a more significant decrease in inflammatory markers for D-dimer (), CRP (), and ferritin (). Conclusions. Our study demonstrates that colchicine improved outcomes in patients with COVID-19 receiving standard of care therapy. Future randomized, placebo-controlled clinical trials to assess the potential benefit of colchicine in COVID-19 are warranted.

中文翻译：

---

评估秋水仙碱对中重度 COVID-19 感染住院患者影响的病例对照研究

背景。秋水仙碱已用于周期性发热性疾病、急性心包炎和痛风性关节炎等疾病，所有这些疾病都具有常见的高​​炎症反应，如 2019 年中度至重度冠状病毒病 (COVID-19) 所示。该项目是在纽约市病例激增期间进行的，目的是评估秋水仙碱治疗 COVID-19 患者的疗效。方法。比较了入住 BronxCare 医院中心两个不同的肺导向楼层的患者。除了标准护理外，一层楼的患者还服用秋水仙碱，而另一层楼的对照患者仅接受标准护理。对四分之二的血清炎症标志物至少进行两次独立时间点测量的患者（选择C-反应蛋白 (CRP)、D-二聚体、铁蛋白或乳酸脱氢酶 (LDH)) 进行最终综合分析。结果。无论是否有两种时间点炎症标志物，对所有患者进行的初步分析显示死亡率较低（49.1% 对 72.9%，)，插管百分比较低（52.8% 对 73.6%，)，以及更高的出院率（50.9% 对 27.1%，)，在接受秋水仙碱的患者中。最终综合分析组的患者（秋水仙碱组 34 例和对照组 78 例）的合并症患病率相似，但肾衰竭在对照组中较高（65.3% 对 35.2%，）。HTN（71.8% 对 52.9%，)和 DM (51.3% 对 32.4%,)在对照组中也更为普遍，尽管差异无统计学意义。接受秋水仙碱的患者死亡率低于对照组（47.1% vs 80.8%，)，插管率较低（47.1% 对 87.2%，)，以及更高的出院率（52.9% 对 19.2%，）。秋水仙碱组患者的D-二聚体炎症标志物也显示出更显着的降低。), CRP ()和铁蛋白 (）。 结论。我们的研究表明，秋水仙碱改善了接受标准护理治疗的 COVID-19 患者的预后。未来有必要进行随机、安慰剂对照的临床试验，以评估秋水仙碱在 COVID-19 中的潜在益处。